Physician profile
Jerome De Vente
NPI 1548208242
$11,120.06
in general payments reported to CMS, 2019-2025
22 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $999 · 2021: $1,125 · 2022: $1,536 · 2023: $2,758 · 2024: $1,961 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895 · Consulting Fee: $1,125 · Travel and Lodging: $820 · Education: $39.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,894.93 |
| Consulting Fee | $1,125.00 |
| Travel and Lodging | $820.46 |
| Education | $39.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,028.64 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $3,677.61 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Theratechnologies INC. | $1,270.74 | 2020-2023 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $591.94 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $415.93 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Abbvie INC. | $240.68 | 2021-2022 | |
| Glaxosmithkline, LLC. | $160.61 | 2019-2022 | |
| Emd Serono, INC. | $118.81 | 2020-2025 | |
| Napo Pharmaceuticals INC | $104.81 | 2019-2024 | Mytesi |
| Janssen Products, Lp | $99.00 | 2020 | |
| Hologic Sales and Service, LLC | $72.75 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $65.37 | 2023-2025 | |
| Novo Nordisk INC | $63.30 | 2022-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $46.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.22 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $36.56 | 2021-2022 | |
| Braeburn INC. | $22.34 | 2025 | Brixadi |
| Paratek Pharmaceuticals, INC. | $21.83 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome De Vente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.